Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine.
Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs. Our value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Biotest manufactures immunoglobulins, clotting factors and albumins which derive from human blood plasma. Biotest also develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest currently employs more than 2,500 people worldwide.
The most important raw material for our pharmaceuticals is human blood plasma, which we process into effective and highly purified drugs in one of our world leading fractionation facilities in Europe. These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders.